QUARTERLY PHARMACY QUALITY ASSURANCE MONITORING RESULTS

| ACTIVITY | FINDINGS / SIGNIFICANT ISSUES | | RECOMMENDATIONS / ACTIONS | FOLLOW UP / EVALUATION |
|--|---|---|---------------------------|---------------------------|
| Medication Monitoring | The criteria review findings were scored and the percentage of compliance calculated. The average percentage of compliance of reviewed is given below. | | | |
| Purpose: | Medication Monitoring Indicators and Percentage of Compliance | % | | |
| To monitor the medication regimen and current FCMH practice within the standard of care. | Medication dosages are within FDA approved guidelines AIMS form is current | | | |
| Objectives: | Medication orders: dosage, schedule, quantity present MD signatures/initials on progress notes and RX sheets | | | |
| (1) Increase the effective use of psychotropic medications | 6. Consumer responding to meds / changes to documented | | | |
| (2) Reduce the inappropriate use of psychotropic medications and likelihood of the occurrence of adverse effects | 7. Consumer on multiple anti-psychotics - Why? 8. Side effects to medications documented 9. Compliance addressed on med sheet | | | |
| (3) Increase knowledge of clinical staff regarding use of psychotropic medications | 10. Lab test drawn for medication requiring blood levels (see below)* 11. Consumer has input into Tx plan / documented | | | |
| (4) Increase individual's treatment compliance with psychotropic medication | Medication consent form current MD notes legible | | | |
| (5) Encourage individual's education about psychotic medications and the role of medication in community functioning | Consumer on Abx / need assessed / Abx appropriate / Length of therapy indicated?* Solution Solu | | | |
| (6) Assure that side effects are measured and documented | monitored* 16. Consumer on HTN meds / BP monitored / Parameters set 17. Consumer meds list reviewed for drug-drug interaction - | | | |
| (7) Assure that informed consent is current | * Represents percent of patients on therapy for that indicator | | | |
| Method: A retrospective chart review was conducted | Notes: All patients reviewed received medications appropriate for diagnosed | | | |
| Number of MDs reviewed: | conditions Lab monitoring was ordered for medications requiring lab monitoring (Clozaril, etc.) | | | |
| Total number of cases reviewed: | Scheduled monitoring was also ordered for medications requiring daily or multi-daily monitoring (BP or oral hypoglycemics) Formulary adherence is important for the program to continue to manage and control drug costs. | | | |
| Reporting Period: | | | | |